drugset / Trial / NCT04618367
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Completed
30 enrolled
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2021-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |